4,028
Views
4
CrossRef citations to date
0
Altmetric
Review Articles

Towards a science-based testing strategy to identify maternal thyroid hormone imbalance and neurodevelopmental effects in the progeny – part II: how can key events of relevant adverse outcome pathways be addressed in toxicological assessments?

ORCID Icon, , , ORCID Icon, , , , , , ORCID Icon, , & ORCID Icon show all
Pages 328-358 | Received 14 Dec 2020, Accepted 26 Mar 2021, Published online: 02 Jun 2021

References

  • Abuid J, Klein AH, Foley TPJ, Larsen PR. 1974. Total and free triiodothyronine and thyroxine in early infancy. J Clin Endocrinol Metab. 39(2):263–268.
  • Alexander EK, Pearce EN, Brent GA, Brown RS, Chen H, Dosiou C, Grobman WA, Laurberg P, Lazarus JH, Mandel SJ, et al. 2017. 2017 Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. Thyroid. 27(3):315–389.
  • Alshehri B, D'Souza DG, Lee JY, Petratos S, Richardson SJ. 2015. The diversity of mechanisms influenced by transthyretin in neurobiology: development, disease and endocrine disruption. J Neuroendocrinol. 27(5):303–323.
  • Arem R, Wiener GJ, Kaplan SG, Kim HS, Reichlin S, Kaplan MM. 1993. Reduced tissue thyroid hormone levels in fatal illness. Metabolism. 42(9):1102–1108.
  • Arrojo E Drigo R, Bianco AC. 2011. Type 2 deiodinase at the crossroads of thyroid hormone action. Int J Biochem Cell Biol. 43(10):1432–1441.
  • Barter RA, Klaassen CD. 1994. Reduction of thyroid hormone levels and alteration of thyroid function by four representative UDP-glucuronosyltransferase inducers in rats. Toxicol Appl Pharmacol. 128(1):9–17.
  • Bartsch R, Brinkmann B, Jahnke G, Laube B, Lohmann R, Michaelsen S, Neumann I, Greim H. 2018. Human relevance of follicular thyroid tumors in rodents caused by non-genotoxic substances. Regulat Toxicol Pharmacol. 98:199–208.
  • Bastian TW, Prohaska JR, Georgieff MK, Anderson GW. 2010. Perinatal iron and copper deficiencies alter neonatal rat circulating and brain thyroid hormone concentrations. Endocrinology. 151(8):4055–4065.
  • Beekhuijzen M, Rijk JCW, Meijer M, de Raaf MA, Pelgrom S. 2019. A critical evaluation of thyroid hormone measurements in OECD test guideline studies: is there any added value? Reprod Toxicol. 88:56–66.
  • Beekhuijzen M, Schneider S, Barraclough N, Hallmark N, Hoberman A, Lordi S, Moxon M, Perks D, Piersma AH, Makris SL. 2018. The urgency for optimization and harmonization of thyroid hormone analyses and their interpretation in developmental and reproductive toxicology studies. Reprod Toxicol. 80:126–130.
  • Beetstra JB, van Engelen JG, Karels P, van der Hoek HJ, de Jong M, Docter R, Krenning EP, Hennemann G, Brouwer A, Visser TJ. 1991. Thyroxine and 3,3',5-triiodothyronine are glucuronidated in rat liver by different uridine diphosphate-glucuronyltransferases. Endocrinology. 128(2):741–746.
  • Bernal J. 2007. Thyroid hormone receptors in brain development and function. Nat Clin Pract Endocrinol Metab. 3(3):249–259.
  • Bernal J. 2015. Thyroid hormones in brain development and function. In: Feingold KR, Anawalt B, Boyce A, editors. Endotext [Internet]. South Dartmouth MA, USA; MDText.com, Inc.
  • Bernal J, Guadaño-Ferraz A, Morte B. 2015. Thyroid hormone transporters-functions and clinical implications. Nat Rev Endocrinol. 11(12):690.
  • Bernal J, Pekonen F. 1984. Ontogenesis of the nuclear 3,5,3'-triiodothyronine receptor in the human fetal brain. Endocrinology. 114(2):677–679.
  • Bianco AC, Anderson G, Forrest D, Galton VA, Gereben B, Kim BW, Kopp PA, Liao XH, Obregon MJ, Peeters RP, et al. 2014. American Thyroid Association guide to investigating thyroid hormone economy and action in rodent and cell models. Thyroid. 24(1):88–168.
  • Bianco AC, Kim BW. 2006. Deiodinases: implications of the local control of thyroid hormone action. J Clin Invest. 116(10):2571–2579.
  • Bianco AC, Salvatore D, Gereben B, Berry MJ, Larsen PR. 2002. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev. 23(1):38–89.
  • Bradley DJ, Young WII, Weinberger C. 1989. Differential expression of alpha and beta thyroid hormone receptor genes in rat brain and pituitary. Proc Natl Acad Sci U S A. 86(18):7250–7254.
  • Bradley DJ, Towle HC, Young WS. 1992. Spatial and temporal expression of alpha- and beta-thyroid hormone receptor mRNAs, including the beta 2-subtype, in the developing mammalian nervous system. J Neurosci. 12(6):2288–2302.
  • Braun D, Kinne A, Bräuer AU, Sapin R, Klein MO, Köhrle J, Wirth EK, Schweizer U. 2011. Developmental and cell type-specific expression of thyroid hormone transporters in the mouse brain and in primary brain cells. Glia. 59(3):463–471.
  • Brouwer A, van den Berg KJ. 1986. Binding of a metabolite of 3,4,3',4'-tetrachlorobiphenyl to transthyretin reduces serum vitamin A transport by inhibiting the formation of the protein complex carrying both retinol and thyroxin. Toxicol Appl Pharmacol. 85(3):301–312.
  • Buckalew AR, Wang J, Murr AS, Deisenroth C, Stewart WM, Stoker TE, Laws SC. 2020. Evaluation of potential sodium-iodide symporter (NIS) inhibitors using a secondary Fischer rat thyroid follicular cell (FRTL-5) radioactive iodide uptake (RAIU) assay. Arch Toxicol. 94(3):873–885.
  • Calvo R, Obregón MJ, Ruiz de Oña C, Escobar del Rey F, Morreale de Escobar G. 1990. Congenital hypothyroidism, as studied in rats. Crucial role of maternal thyroxine but not of 3,5,3′-triiodothyronine in the protection of the fetal brain. J Clin Invest. 86(3):889–899.
  • Carvalho DP, Ferreira ACF, Coelho SM, Moraes JM, Camacho MAS, Rosenthal D. 2000. Thyroid peroxidase activity is inhibited by amino acids. Braz J Med Biol Res. 33(3):355–361.
  • Cavalieri RR, Pitt-Rivers R. 1981. The effects of drugs on the distribution and metabolism of thyroid hormones. Pharmacol Rev. 33(2):55–80.
  • Ceballos A, Belinchon MM, Sanchez-Mendoza E, Grijota-Martinez C, Dumitrescu AM, Refetoff S, Morte B, Bernal J. 2009. Importance of monocarboxylate transporter 8 for the blood-brain barrier-dependent availability of 3,5,3'-triiodo-L-thyronine. Endocrinology. 150(5):2491–2496.
  • Chakravarthy V, Ejaz S. 2020. Thyroxine-binding globulin deficiency. In: StatPearls. Treasure Island FL, USA; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK544274/
  • Chan S, Kachilele S, McCabe CJ, Tannahill LA, Boelaert K, Gittoes NJ, Visser TJ, Franklyn JA, Kilby MD. 2002. Early expression of thyroid hormone deiodinases and receptors in human fetal cerebral cortex. Brain Res Dev Brain Res. 138(2):109–116.
  • Chang L, Munro SL, Richardson SJ, Schreiber G. 1999. Evolution of thyroid hormone binding by transthyretins in birds and mammals. Eur J Biochem. 259(1–2):534–542.
  • Chan SY, Hancox LA, Martín-Santos A, Loubière LS, Walter MNM, González A-M, Cox PM, Logan A, McCabe CJ, Franklyn JA, et al. 2014. MCT8 expression in human fetal cerebral cortex is reduced in severe intrauterine growth restriction. J Endocrinol. 220(2):85–95.
  • Chanoine JP, Braverman LE. 1992. The role of transthyretin in the transport of thyroid hormone to cerebrospinal fluid and brain. Acta Med Austriaca. 19(Suppl 1):25–28.
  • Cheng SY, Leonard JL, Davis PJ. 2010. Molecular aspects of thyroid hormone actions. Endocr Rev. 31(2):139–170.
  • Choksi NY, Jahnke GD, St Hilaire C, Shelby M. 2003. Role of thyroid hormones in human and laboratory animal reproductive health. Birth Defects Res B Dev Reprod Toxicol. 68(6):479–491.
  • Chopra IJ, Wu SY, Teco GN, Santini F. 1992. A radioimmunoassay for measurement of 3,5,3'-triiodothyronine sulfate: studies in thyroidal and nonthyroidal diseases, pregnancy, and neonatal life. J Clin Endocrinol Metab. 75(1):189–194.
  • Colnot T, Dekant W. 2017. Approaches for grouping of pesticides into cumulative assessment groups for risk assessment of pesticide residues in food. Regul Toxicol Pharmacol. 83:89–99.
  • Crofton KM. 1990. Reflex modification and the detection of toxicant-induced auditory dysfunction. Neurotox Teratol. 12(5):461–468.
  • Crofton KM, Gilbert M, Friedman KP, Demeneix B, Marty MS, Zoeller RT. 2019. Adverse outcome pathway on inhibition of thyroperoxidase and subsequent adverse neurodevelopmental outcomes in mammals. OECD Series on Adverse Outcome. Pathways, No. 13. DOI:10.1787/ea5aa069-en
  • Crofton KM, Kodavanti PR, Derr-Yellin EC, Casey AC, Kehn LS. 2000. PCBs, thyroid hormones, and ototoxicity in rats: cross-fostering experiments demonstrate the impact of postnatal lactation exposure. Toxicol Sci. 57(1):131–140.
  • Crofton KM, Zoeller RT. 2005. Mode of action: Neurotoxicity induced by thyroid hormone disruption during development-hearing loss resulting from exposure to PHAHs. Crit Rev Toxicol. 35(8–9):757–769.
  • Darras VM, Hume R, Visser TJ. 1999. Regulation of thyroid hormone metabolism during fetal development. Mol Cell Endocrinol. 151(1–2):37–47.
  • Darras VM, van Herck SL. 2012. Iodothyronine deiodinase structure and function: from ascidians to humans. J Endocrinol. 215(2):189–206.
  • Dayem M, Basquin C, Navarro V, Carrier P, Marsault R, Chang P, Huc S, Darrouzet E, Lindenthal S, Pourcher T. 2008. Comparison of expressed human and mouse sodium/iodide symporters reveals differences in transport properties and subcellular localization. J Endocrinol. 197(1):95–109.
  • Deisenroth C, Soldatow VY, Ford J, Stewart W, Brinkman C, LeCluyse EL, MacMillan DK, Thomas RS. 2020. Development of an in vitro human thyroid microtissue model for chemical screening. Toxicol Sci. 174(1):63–78.
  • DeVito M, Biegel L, Brouwer A, Brown S, Brucker-Davis F, Cheek AO, Christensen R, Colborn T, Cooke P, Crissman J, et al. 1999. Screening methods for thyroid hormone disruptors. Environ Health Perspect. 107(5):407–415.
  • Divi RL, Doerge DR. 1996. Inhibition of thyroid peroxidase by dietary flavonoids. Chem Res Toxicol. 9(1):16–23.
  • Dong H, Godlewska M, Wade MG. 2020. A rapid assay of human thyroid peroxidase activity. Toxicol in Vitro. 62:104662.
  • Emi Y, Ikushiro S, Kato Y. 2007. Thyroxine-metabolizing rat uridine diphosphate-glucuronosyltransferase 1A7 is regulated by thyroid hormone receptor. Endocrinology. 148(12):6124–6133.
  • European Commission. 2017. Commission Delegated Regulation (EU) 2017/2100 of 4 September 2017 setting out scientific criteria for the determination of endocrine-disrupting properties pursuant to Regulation (EU) No 528/2012 of the European Parliament and Council. OJ EU L. 60:1–12.
  • European Commission. 2018. Commission Regulation (EU) 2018/605 of 19 April 2018 amending Annex II to Regulation (EC) No 1107/2009 by setting out criteria for the determination of endocrine disrupting properties. OJ EU L. 101:33–36.
  • European Food Safety Authority [EFSA]. 2020. Technical report on the outcome of the pesticides peer review meeting on general recurring issues in mammalian toxicology. EFSA Supporting Publication. 2020:EN-1837. DOI:https://doi.org/10.2903/sp.efsa.2020.EN-1837
  • European Food Safety Authority, European Chemicals Agency [EFSA, ECHA]. 2018. European Food Safety Authority and European Chemicals Agency with the technical support of the Joint Research Centre (Andersson N, Arena M, Auteri D, Barmaz S, Grignard E, Kienzler A, Lepper P, Lostia AM, Munn S, Parra Morte JM, et al.). Guidance for the identification of endocrine disruptors in the context of Regulations (EU) No 528/2012 and (EC) No 1107/2009. ECHA-18-G-01-EN; EFSA J. 16:1661–170.
  • European Parliament and Council [EP and Council]. 2009. Regulation (EC) No 1107/2009 of the European Parliament and of the Council concerning the placing of plant protection products on the market. OJ L. 309:1–50.
  • European Parliament and Council [EP and Council]. 2012. Regulation (EU) No 528/2012 of the European Parliament and of the Council of 22 May 2012 concerning the making available on the market and use of biocidal products. OJ L. 167:1.
  • Fang HL, Shenoy S, Duanmu Z, Kocarek TA, Runge-Morris M. 2003. Transactivation of glucocorticoid-inducible rat aryl sulfotransferase (SULT1A1) gene transcription. Drug Metab Dispos. 31(11):1378–1381.
  • Findlay KA, Kaptein E, Visser TJ, Burchell B. 2000. Characterization of the uridine diphosphate-glucuronosyltransferase-catalyzing thyroid hormone glucuronidation in man. J Clin Endocrinol Metab. 85(8):2879–2883.
  • Flamant F, Baxter JD, Forrest D, Refetoff S, Samuels H, Scanlan TS, Vennström B, Samarut J. 2006. International Union of Pharmacology. LIX. The pharmacology and classification of the nuclear receptor superfamily: thyroid hormone receptors. Pharmacol Rev. 58(4):705–711.
  • Fleming CE, Nunes AF, Sousa MM. 2009. Transthyretin: more than meets the eye. Prog Neurobiol. 89(3):266–276.
  • Franchi SA, Macco R, Astro V, Tonoli D, Savino E, Valtorta F, Sala K, Botta M, de CI. 2017. A method to culture GABAergic interneurons derived from the medial ganglionic eminence. Front Cell Neurosci. 11:423.
  • Friesema EC, Docter R, Moerings EP, Stieger B, Hagenbuch B, Meier PJ, Krenning EP, Hennemann G, Visser TJ. 1999. Identification of thyroid hormone transporters. Biochem Biophys Res Commun. 254(2):497–501.
  • Galton VA, McCarthy PT, St Germain DL. 1991. The ontogeny of iodothyronine deiodinase systems in liver and intestine of the rat. Endocrinology. 128(4):1717–1722.
  • Gardner-Stephen D, Heydel JM, Goyal A, Lu Y, Xie W, Lindblom T, Mackenzie P, Radominska-Pandya A. 2004. Human PXR variants and their differential effects on the regulation of human UDP-glucuronosyltransferase gene expression. Drug Metab Dispos. 32(3):340–347.
  • Gereben B, Salvatore D, Harney JW, Tu HM, Larsen PR. 2001. The human, but not rat, dio2 gene is stimulated by thyroid transcription factor-1 (TTF-1). Mol Endocrinol. 15(1):112–124.
  • Gereben B, Zavacki AM, Ribich S, Kim BW, Huang SA, Simonides WS, Zeöld A, Bianco AC. 2008. Cellular and molecular basis of deiodinase-regulated thyroid hormone signaling. Endocr Rev. 29(7):898–938.
  • Grijota-Martinez C, Diez D, Morreale de Escobar G, Bernal J, Morte B. 2011. Lack of action of exogenously administered T3 on the fetal rat brain despite expression of the monocarboxylate transporter 8. Endocrinology. 152(4):1713–1721.
  • Hadlow NC, Rothacker KM, Wardrop R, Brown SJ, Lim EM, Walsh JP. 2013. The relationship between TSH and free T4 in a large population is complex and nonlinear and differs by age and sex. J Clin Endocrinol Metab. 98(7):2936–2943.
  • Hallgren S, Darnerud PO. 2002. Polybrominated diphenyl ethers (PBDEs), polychlorinated biphenyls (PCBs) and chlorinated paraffins (CPs) in rats – testing interactions and mechanisms for thyroid hormone effects. Toxicol. 177(2-3):227–243.
  • Hallinger DR, Murr AS, Buckalew AR, Simmons SO, Stoker TE, Laws SC. 2017. Development of a screening approach to detect thyroid disrupting chemicals that inhibit the human sodium iodide symporter (NIS). Toxicol in Vitro. 40:66–78.
  • Hamers T, Kamstra JH, Sonneveld E, Murk AJ, Visser TJ, Van Velzen MJ, Brouwer A, Bergman A. 2008. Biotransformation of brominated flame retardants into potentially endocrine-disrupting metabolites, with special attention to 2,2',4,4'-tetrabromodiphenyl ether (BDE-47)). Mol Nutr Food Res. 52(2):284–298.
  • Hassan I, El-Masri H, Ford J, Brennan A, Handa S, Paul Friedman K, Gilbert ME. 2020. Extrapolating in vitro screening assay data for thyroperoxidase inhibition to predict serum thyroid hormones in the rat. Toxicol Sci. 173(2):280–292.
  • Hassan I, Hisham E-M, Kosian PA, Ford J, Degitz SJ, Gilbert ME. 2017. Neurodevelopmental and thyroid hormone synthesis inhibition in the rat: quantitative understanding within the adverse outcome pathway framework. Tox Sci. 160(1):57–73.
  • Heltemes LM, Hagan CR, Mitrofanova EE, Panchal RG, Guo J, Link CJ. 2003. The rat sodium iodide symporter gene permits more effective radioisotope concentration than the human sodium iodide symporter gene in human and rodent cancer cells. Cancer Gene Ther. 10(1):14–22.
  • Hempel N, Wang H, LeCluyse EL, McManus ME, Negishi M. 2004. The human sulfotransferase SULT1A1 gene is regulated in a synergistic manner by Sp1 and GA binding protein. Mol Pharmacol. 66(6):1690–1701.
  • Hill RN, Erdreich LS, Paynter OE, Roberts PA, Rosenthal SL, Wilkinson CF. 1989. Thyroid follicular cell carcinogenesis. Fundam Appl Toxicol. 12(4):629–697.
  • Holtorf K. 2014. Thyroid hormone transport into cellular tissue. j Restorat Med. 3(1):53–68.
  • Hornung MW, Korte JJ, Olker JH, Denny JS, Knutsen C, Hartig PC, Cardon MC, Degitz SJ. 2018. Screening the ToxCast phase 1 chemical library for inhibition of deiodinase type 1 activity. Toxicol Sci. 162(2):570–581.
  • Huang SA, Bianco AC. 2008. Reawakened interest in type III iodothyronine deiodinase in critical illness and injury. Nat Clin Pract Endocrinol Metab. 4(3):148–155.
  • Huang SA, Dorfman DM, Genest DR, Salvatore D, Larsen PR. 2003. Type 3 iodothyronine deiodinase is highly expressed in the human uteroplacental unit and in fetal epithelium. J Clin Endocrinol Metab. 88(3):1384–1388.
  • Huisinga M, Bertrand L, Chamanza R, Damiani I, Engelhardt J, Francke S, Freyberger A, Harada T, Harleman J, Kaufmann W, et al. 2020. Adversity considerations for thyroid follicular cell hypertrophy and hyperplasia in nonclinical toxicity studies: results from the 6th ESTP International Expert Workshop. Toxicol Pathol. 48(8):920–938.
  • Ichihara K, Ozarda Y, Barth JH, Klee G, Qiu L, Erasmus R, Borai A, Evgina S, Ashavaid T, Khan D, et al. 2017. A global multicenter study on reference values: 1. Assessment of methods for derivation and comparison of reference intervals. Clin Chim Acta. 467:70–82.
  • Jahnke GD, Choksi NY, Moore JA, Shelby MD. 2004. Thyroid toxicants: assessing reproductive health effects. Environ Health Perspect. 112(3):363–368.
  • Jansen TA, Korevaar TIM, Mulder TA, White T, Muetzel RL, Peeters RP, Tiemeier H. 2019. Maternal thyroid function during pregnancy and child brain morphology: a time window-specific analysis of a prospective cohort. Lancet Diabetes Endocrinol. 7(8):629–637.
  • Jomaa B, de Haan LH, Peijnenburg AA, Bovee TF, Aarts JM, Rietjens IM. 2015. Simple and rapid in vitro assay for detecting human thyroid peroxidase disruption. ALTEX. 32(3):191–200.
  • Jonklaas J, Sathasivam A, Wang H, Gu J, Burman KD, Soldin SJ. 2014. Total and free thyroxine and triiodothyronine: measurement discrepancies, particularly in inpatients. Clin Biochem. 47(13-14):1272–1278.
  • Jusko TA, Sisto R, Iosif AM, Moleti A, Wimmerová S, Lancz K, Tihányi J, Sovčiková E, Drobná B, Palkovičová L, et al. 2014. Prenatal and postnatal serum PCB concentrations and cochlear function in children at 45 months of age. Environ Health Perspect. 122(11):1246–1252.
  • Kaptein EM, Hays MT, Ferguson DC. 1994. Thyroid hormone metabolism. Vet Clin North Am Small Anim Pract. 24(3):431–462.
  • Kester MH, Kaptein E, Roest TJ, van Dijk CH, Tibboel D, Meinl W, Glatt H, Coughtrie MW, Visser TJ. 1999. Characterization of human iodothyronine sulfotransferases. J Clin Endocrinol Metab. 84(4):1357–1364.
  • Kester MHA, Kaptein E, Roest TJ, van Dijk CH, Tibboel D, Meinl W, Glatt H, Coughtrie MWH, Visser TJ. 2003. Characterization of rat iodothyronine sulfotransferases. Am J Physiol Endocrinol Metab. 285(3):E592–E598.
  • Kester MH, Kaptein E, van Dijk CH, Roest TJ, Tibboel D, Coughtrie MW, Visser TJ. 2002. Characterization of iodothyronine sulfatase activities in human and rat liver and placenta. Endocrinology. 143(3):814–819.
  • Klaassen CD, Hood AM. 2001. Effects of microsomal enzyme inducers on thyroid follicular cell proliferation and thyroid hormone metabolism. Toxicol Pathol. 29(1):34–40.
  • Kliewer SA, Willson TM. 2002. Regulation of xenobiotic and bile acid metabolism by the nuclear pregnane X receptor. J Lipid Res. 43(3):359–364.
  • Knapen D, Angrish MM, Fortin MC, Katsiadaki I, Leonard M, Margiotta-Casaluci L, Munn S, O'Brien JM, Pollesch N, Smith LC, et al. 2018. Adverse outcome pathway networks I: Development and applications. Environ Toxicol Chem. 37(6):1723–1733.
  • Köhrle J. 2002. Iodothyronine deiodinases. Methods Enzymol. 347:125–167.
  • Korevaar TIM, Muetzel R, Medici M, Chaker L, Jaddoe VWV, de Rijke YB, Steegers EAP, Visser TJ, White T, Tiemeier H, et al. 2016. Association of maternal thyroid function during early pregnancy with offspring IQ and brain morphology in childhood: a population-based prospective cohort study. Lancet Diabetes Endocrinol. 4(1):35–43.
  • Lans MC, Spiertz C, Brouwer A, Koeman JH. 1994. Different competition of thyroxine binding to transthyretin and thyroxine-binding globulin by hydroxy-PCBs, PCDDs and PCDFs. Eur J Pharmacol. 270(2–3):129–136.
  • Lee JY, Kim MJ, Deliyanti D, Azari MF, Rossello F, Costin A, Ramm G, Stanley EG, Elefanty AG, Wilkinson-Berka JL, et al. 2017. Overcoming monocarboxylate transporter 8 (MCT8)-deficiency to promote human oligodendrocyte differentiation and myelination. EBioMedicine. 25:122–135.
  • Lewandowski TA, Seeley MR, Beck BD. 2004. Interspecies differences in susceptibility to perturbation of thyroid homeostasis: a case study with perchlorate. Regul Toxicol Pharmacol. 39(3):348–362.
  • Li AA, Makris SL, Marty MS, Strauss V, Gilbert ME, Blacker A, Zorrilla LM, Coder PS, Hannas B, Lordi S, et al. 2019. Practical considerations for developmental thyroid toxicity assessments: what's working, what's not, and how can we do better? Regul Toxicol Pharmacol. 106:111–136.
  • Little AG. 2018. Local regulation of thyroid hormone signaling. Vitam Horm. 106:1–17.
  • Liu J, Liu Y, Barter RA, Klaassen CD. 1995. Alteration of thyroid homeostasis by UDP-glucuronosyltransferase inducers in rats: a dose-response study. J Pharmacol Exp Ther. 273(2):977–985.
  • Loeb WF, Quimby FW. 1999. The clinical chemistry of laboratory animals. New York: Pergamon Press.
  • Longnecker MP, Hoffman HJ, Klebanoff MA, Brock JW, Zhou H, Needham L, Adera T, Guo X, Gray KA. 2004. In utero exposure to polychlorinated biphenyls and sensorineural hearing loss in 8-year-old children. Neurotoxicol Teratol. 26(5):629–637.
  • Maglich JM, Watson J, McMillen PJ, Goodwin B, Willson TM, Moore JT. 2004. The nuclear receptor CAR is a regulator of thyroid hormone metabolism during caloric restriction. J Biol Chem. 279(19):19832–19838.
  • Maia AL, Goemann IM, Meyer EL, Wajner SM. 2011. Deiodinases: the balance of thyroid hormone: type 1 iodothyronine deiodinase in human physiology and disease. J Endocrinol. 209(3):283–297.
  • Maia AL, Kim BW, Huang SA, Harney JW, Larsen PR. 2005. Type 2 iodothyronine deiodinase is the major source of plasma T3 in euthyroid humans. J Clin Invest. 115(9):2524–2533.
  • Makris SL, Raffaele K, Allen S, Bowers WJ, Hass U, Alleva E, Calamandrei G, Sheets L, Amcoff P, Delrue N, et al. 2009. A retrospective performance assessment of the developmental neurotoxicity study in support of OECD test guideline 426. Environ Health Perspect. 117(1):17–25.
  • Marty MS, Borgert C, Coady K, Green R, Levine SL, Mihaich E, Ortego L, Wheeler JR, Yi KD, Zorrilla LM. 2018. Distinguishing between endocrine disruption and non-specific effects on endocrine systems. Regul Toxicol Pharmacol. 99:142–158.
  • McClain RM. 1989. The significance of hepatic microsomal enzyme induction and altered thyroid function in rats: implications for thyroid gland neoplasia. Toxicol Pathol. 17(2):294–306.
  • Meek ME, Boobis A, Cote I, Dellarco V, Fotakis G, Munn S, Seed J, Vickers C. 2014. New developments in the evolution and application of the WHO/IPCS framework on mode of action/species concordance analysis. J Appl Toxicol. 34(1):1–18.
  • Meek MEB, Palermo CM, Bachman AN, North CM, Jeffrey Lewis R. 2014. Mode of action human relevance (species concordance) framework: Evolution of the Bradford Hill considerations and comparative analysis of weight of evidence. J Appl Toxicol. 34(6):595–606.
  • Mendoza A, Hollenberg AN. 2017. New insights into thyroid hormone action. Pharmacol Ther. 173:135–145.
  • Middaugh LD, Dow-Edwards D, Li AA, Sandler JD, Seed J, Sheets LP, Shuey DL, Slikker W, Jr, Weisenburger WP, Wise LD, et al. 2003. Neurobehavioral assessment: a survey of use and value in safety assessment studies. Toxicol Sci. 76(2):250–261.
  • Midgley JEM, Toft AD, Larisch R, Dietrich JW, Hoermann R. 2019. Time for a reassessment of the treatment of hypothyroidism. BMC Endocr Disord. 19(1):37.
  • Mol JA, Visser TJ. 1985. Rapid and selective inner ring deiodination of thyroxine sulfate by rat liver deiodinase. Endocrinol. 117(1):8–12.
  • Morreale de Escobar G, Calvo R, Obregon MJ, Escobar del Rey F. 1990. Contribution of maternal thyroxine to fetal thyroxine pools in normal rats near term. Endocrinology. 126(5):2765–2777.
  • Morreale de Escobar G, Pastor R, Obregon MJ, Escobar del Rey F. 1985. Effects of maternal hypothyroidism on the weight and thyroid hormone content of rat embryonic tissues, before and after onset of fetal thyroid function. Endocrinol. 117(5):1890–1900.
  • Morreale de Escobar GM, Obregón MJ, del Rey FE. 2004. Maternal thyroid hormones early in pregnancy and fetal brain development. Best Pract Res Clin Endocrinol Metab. 18(2):225–248.
  • Murk AJ, Rijntjes E, Blaauboer BJ, Clewell R, Crofton KM, Dingemans MML, Furlow JD, Kavlock R, Köhrle J, Opitz R, et al. 2013. Mechanism-based testing strategy using in vitro approaches for identification of thyroid hormone disrupting chemicals. Toxicol in Vitro. 27(4):1320–1346.
  • Neal C, Kennon-McGill S, Freemyer A, Shum A, Staecker H, Durham D. 2015. Hair cell counts in a rat model of sound damage: effects of tissue preparation & identification of regions of hair cell loss. Hear Res. 328:120–132.
  • Noyes PD, Friedman KP, Browne P, Haselman JT, Gilbert ME, Hornung MW, Barone S, Jr, Crofton KM, Laws SC, Stoker TE, et al. 2019. Evaluating chemicals for thyroid disruption: opportunities and challenges with in vitro testing and adverse outcome pathway approaches. Environ Health Perspect. 127(9):95001.
  • Olker JH, Korte JJ, Denny JS, Hartig PC, Cardon MC, Knutsen CN, Kent PM, Christensen JP, Degitz SJ, Hornung MW. 2019. Screening the ToxCast Phase 1, Phase 2, and e1k Chemical Libraries for inhibitors of iodothyronine deiodinases. Toxicol Sci. 168(2):430–442.
  • Organisation for Economic Cooperation and Development [OECD]. 2014. Series on testing and assessment No. 207. New scoping document on in vitro and ex vivo assays for the identification of modulators of thyroid hormone signaling. ENV/JM/MONO(2014)23. Paris, France: OECD.
  • Organisation for Economic Cooperation and Development [OECD]. 2017. Series on testing and assessment No. 184. Revised guidance document on developing and assessing adverse outcome pathways. ENV/JM/MONO(2013)6. Paris, France: OECD.
  • Organisation for Economic Cooperation and Development [OECD]. 2018. Adverse outcome pathway external review report. AOP 54: inhibition of Na+/I- symporter (NIS) decreases TH synthesis leading to learning and memory deficits in children [accessed 2020 Sep] https://aopwiki.org/system/dragonfly/production/2018/07/03/9nmpr7rl2_AOP_54_External_review_report.pdf.
  • O'Shaughnessy KL, Wood C, Ford RL, Kosian PA, Hotchkiss MG, Degitz SJ, Gilbert ME. 2018. Thyroid hormone disruption in the fetal and neonatal rat: Predictive hormone measures and bioindicators of hormone action in the developing cortex. Toxicol Sci. 166(1):163–179.
  • Palazzi X, Burkhardt JE, Caplain H, Dellarco V, Fant P, Foster JR, Francke S, Germann P, Gröters S, Harada T, et al. 2016. Characterizing “adversity” of pathology findings in nonclinical toxicity studies: results from the 4th ESTP International Expert Workshop. Toxicol Pathol. 44(6):810–824.
  • Palha JA. 2002. Transthyretin as a thyroid hormone carrier: function revisited. Clin Chem Lab Med. 40(12):1292–1300.
  • Palha JA, Fernandes R, de Escobar GM, Episkopou V, Gottesman M, Saraiva MJ. 2000. Transthyretin regulates thyroid hormone levels in the choroid plexus, but not in the brain parenchyma: study in a transthyretin-null mouse model. Endocrinology. 141(9):3267–3272.
  • Patel J, Landers K, Li H, Mortimer RH, Richard K. 2011. Delivery of maternal thyroid hormones to the fetus. Trends Endocrinol Metab. 22(5):164–170.
  • Paul Friedman K, Watt ED, Hornung MW, Hedge JM, Judson RS, Crofton KM, Houck KA, Simmons SO. 2016. Tiered high-throughput screening approach to identify thyroperoxidase inhibitors within the ToxCast phase I and II chemical libraries. Toxicol Sci. 151(1):160–180.
  • Paul KB, Hedge JM, Macherla C, Filer DL, Burgess E, Simmons SO, Crofton KM, Hornung MW. 2013. Cross-species analysis of thyroperoxidase inhibition by xenobiotics demonstrates conservation of response between pig and rat. Toxicology. 312:97–107.
  • Paul-Friedman K, Martin M, Crofton KM, Hsu C-W, Sakamuru S, Zhao J, Xia M, Huang R, Stavreva DA, Soni V, et al. 2019. Limited chemical structural diversity found to modulate thyroid hormone receptor in the Tox21 chemical library. Env Health Perspecti. 127(9):97009.
  • Peeters RP, van der Geyten S, Wouters PJ, Darras VM, van Toor H, Kaptein E, Visser TJ, Van den Berghe G. 2005. Tissue thyroid hormone levels in critical illness. J Clin Endocrinol Metab. 90(12):6498–6507.
  • Perez-Castillo A, Bernal J, Ferreiro B, Pans T. 1985. The early ontogenesis of thyroid hormone receptor in the rat fetus. Endocrinology. 117(6):2457–2461.
  • Pilz PK, Schnitzler HU, Menne D. 1987. Acoustic startle threshold of the albino rat (Rattus norvegicus). J Comp Psychol. 101(1):67–72.
  • Pinna G, Hiedra L, Prengel H, Broedel O, Eravci M, Meinhold H, Baumgartner A. 1999. Extraction and quantification of thyroid hormones in selected regions and subcellular fractions of the rat brain. Brain Res Brain Res Protoc. 4(1):19–28.
  • Pohlenz J, Refetoff S. 1999. Mutations in the sodium/iodide symporter (NIS) gene as a cause for iodide transport defects and congenital hypothyroidism. Biochimie. 81(5):469–476.
  • Refetoff S. 2015. Thyroid hormone serum transport proteins. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, Dungan K, Grossman A, Hershman JM, Kaltsas G, Koch C, Kopp P, editors. Endotext [Internet]. South Dartmouth MA, USA: MDText.com, Inc.
  • Renko K, Schäche S, Hoefig CS, Welsink T, Schwiebert C, Braun D, Becker N-P, Köhrle J, Schomburg L. 2015. An improved nonradioactive screening method identifies genistein and xanthohumol as potent inhibitors of iodothyronine deiodinases. Thyroid. 25(8):962–968.
  • Richard K, Hume R, Kaptein E, Sanders JP, van Toor H, de Herder WW, den Hollander JC, Krenning E, Visser TJ. 1998. Ontogeny of iodothyronine deiodinases in human liver. J Clin Endocrinol Metab. 83(8):2868–2874.
  • Richardson VM, Ferguson SS, Sey YM, DeVito MJ. 2014. In vitro metabolism of thyroxine by rat and human hepatocytes. Xenobiotica. 44(5):391–403.
  • Riutta C, Hassan I, Ford J, Kosian P, O’Shaughnessy K, Degitz S, Gilbert M. 2019. Thyroid hormone measurements in rat brain by mass spectrometry. San Diego CA, USA: Development Neurotoxicol Society. p. 23–26.
  • Roche. 2009. Elecsys thyroid tests. Reference intervals for children and adults. D-Mannheim: Roche Diagnostics GmbH.
  • Rolaki A, Pistollato F, Munn S, Price AB. 2019. Adverse outcome pathway on inhibition of Na+/I- symporter (NIS) leads to learning and memory impairment. OECD Series on Adverse Outcome Pathways No. 14. DOI:https://doi.org/10.1787/7ca86a34-en
  • Roques BB, Lacroix MZ, Puel S, Gayrard V, Picard-Hagen N, Jouanin I, Perdu E, Martin PG, Viguié C. 2012. CYP450-dependent biotransformation of the insecticide fipronil into fipronil sulfone can mediate fipronil-induced thyroid disruption in rats. Toxicol Sci. 127(1):29–41.
  • Rousset B, Dupuy C, Miot F, Dumont J, 2015. Chapter 2: thyroid hormone synthesis and secretion. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, Dungan K, Grossman A, Hershman JM, Kaltsas G, Koch C, Kopp P, editors. Endotext [Internet]. South Dartmouth MA, USA; MDText.com, Inc.
  • Ruiz de Oña C, Morreale de Escobar G, Calvo R, Escobar del Rey F, Obregon MJ. 1991. Thyroid hormones and 5'-deiodinase in the rat fetus late in gestation: effects of maternal hypothyroidism. Endocrinology. 128(1):422–432.
  • Ruiz de Oña C, Obregon MJ, Escobar del Rey F, Morreale de Escobar G. 1988. Developmental changes in rat brain 5'-deiodinase and thyroid hormones during the fetal period: the effects of fetal hypothyroidism and maternal thyroid hormones. Pediatr Res. 24(5):588–594.
  • Santini F, Chopra IJ, Wu SY, Solomon DH, Chua Teco GN. 1992. Metabolism of 3,5,3'-triiodothyronine sulfate by tissues of the fetal rat: a consideration of the role of desulfation of 3,5,3'-triiodothyronine sulfate as a source of T3. Pediatr Res. 31(6):541–544.
  • Santini F, Hurd RE, Lee B, Chopra IJ. 1993. Thyromimetic effects of 3,5,3'-triiodothyronine sulfate in hypothyroid rats. Endocrinology. 133(1):105–110.
  • Sauer UG, Asiimwe A, Botham PA, Charlton A, Hallmark N, Jacobi S, Marty S, Melching-Kollmuss S, Palha JA, Strauss V, et al. 2020. Towards a science-based testing strategy to identify maternal thyroid hormone imbalance and neurodevelopmental effects in the progeny – part I: which parameters from human studies are most relevant for toxicological assessments? Crit Rev Toxicol. 11:1–24.
  • Schnell C, Shahmoradi A, Wichert SP, Mayerl S, Hagos Y, Heuer H, Rossner MJ, Hülsmann S. 2015. The multispecific thyroid hormone transporter OATP1C1 mediates cell-specific sulforhodamine 101-labeling of hippocampal astrocytes. Brain Struct Funct. 220(1):193–203.
  • Schoenmakers CHH, Pigmans IGAJ, Visser TJ. 1992. Species differences in liver type I iodothyronine deiodinase. Biochim Biophys Acta. 1121(1–2):160–166.
  • Schussler GC, Ingbar SH, Eveleth P. 1961. The role of intermediary carbohydrate metabolism in regulating organic iodinations in the thyroid gland. J Clin Invest. 40:1394–1412.
  • Schussler GC, Schaffner F, Korn F. 1978. Increased serum thyroid hormone binding and decreased free hormone in chronic active liver disease. N Engl J Med. 299(10):510–515.
  • Sharlin DS, Gilbert ME, Taylor MA, Ferguson DC, Zoeller RT. 2010. The nature of the compensatory response to low thyroid hormone in the developing brain. J Neuroendocrinol. 22(3):153–165.
  • Smanik PA, Liu Q, Furminger TL, Ryu K, Xing S, Mazzaferri EL, Jhiang SM. 1996. Cloning of the human sodium lodide symporter. Biochem Biophys Res Commun. 226(2):339–345.
  • Soldin OP, Soldin SJ. 2011. Thyroid hormone testing by tandem mass spectrometry. Clin Biochem. 44(1):89–94.
  • Stockigt JR. 2001. Free thyroid hormone measurement – a critical appraisal. Assess Thyr Funct Dis. 30(2):265–289.
  • Szabo DT, Richardson VM, Ross DG, Diliberto JJ, Kodavanti PRS, Birnbaum LS. 2009. Effects of perinatal PBDE exposure on hepatic phase I, phase II, phase III, and deiodinase 1 gene expression involved in thyroid hormone metabolism in male rat pups. Toxicol Sci. 107(1):27–39.
  • Takayama S, Aihara K, Onodera T, Akimoto T. 1986. Antithyroid effects of propylthiouracil and sulfamonomethoxine in rats and monkeys. Toxicol Appl Pharmacol. 82(2):191–199.
  • Taylor PM, Ritchie JW. 2007. Tissue uptake of thyroid hormone by amino acid transporters. Best Pract Res Clin Endocrinol Metab. 21(2):237–251.
  • Thorpe-Beeston JG, Nicolaides KH, Felto CV, Butler J, McGregor AM. 1991. Maturation of the secretion of thyroid hormone and thyroid-stimulating hormone in the fetus. N Engl J Med. 324(8):532–536.
  • Tien ES, Negishi M. 2006. Nuclear receptors CAR and PXR in the regulation of hepatic metabolism. Xenobiotica. 36(10–11):1152–1163.
  • Tietge JE, Degitz SJ, Haselman JT, Butterworth BC, Korte JJ, Kosian PA, Lindberg-Livingston AJ, Burgess EM, Blackshear PE, Hornung MW. 2013. Inhibition of the thyroid hormone pathway in Xenopus laevis by 2-mercaptobenzothiazole. Aquat Toxicol. 126:128–136.
  • US Environmental Protection Agency [US EPA]. 2005. Guidance for thyroid assays in pregnant animals, fetuses and postnatal animals, and adult animals. Washington (DC): US EPA, Office of Pesticide Programs, Health Effects Division.
  • US Environmental Protection Agency [US EPA]. 2013. Endocrine disruptor screening program tier 1 assays: considerations for use in human health and ecological risk assessments. Office of Chemical Safety and Pollution Prevention, June 2013; https://www.epa.gov/sites/production/files/2015-07/documents/use_of_tier_1_data_in_risk_assessment.pdf.
  • US Environmental Protection Agency [US EPA]. 2017. Endocrine disruptor screening program. Continuing development of alternative high-throughput screens to determine endocrine disruption, focusing on androgen receptor, steroidogenesis, and thyroid pathways. FIFRA SAP November 28–30, 2017. https://cfpub.epa.gov/si/si_public_record_report.cfm?dirEntryId=338571.
  • Villeneuve DL, Angrish MM, Fortin MC, Katsiadaki I, Leonard M, Margiotta-Casaluci L, Munn S, O'Brien JM, Pollesch NL, Smith LC, et al. 2018. Adverse outcome pathway networks II: network analytics. Environ Toxicol Chem. 37(6):1734–1748.
  • Vinken M, Knapen D, Vergauwen L, Hengstler JG, Angrish M, Whelan M. 2017. Adverse outcome pathways: a concise introduction for toxicologists. Arch Toxicol. 91(11):3697–3707.
  • Visser TJ. 1994. Role of sulfation in thyroid hormone metabolism. Chem Biol Interact. 92(1–3):293–303.
  • Visser TJ. 1996. Pathways of thyroid hormone metabolism. Acta Med Austriaca. 23(1–2):10–16.
  • Visser TJ. 2016. Thyroid hormone transport across the placenta. Ann Endocrinol. 77(6):680–683.
  • Visser TJ, Kaptein E, Gijzel AL, de Herder WW, Ebner T, Burchell B. 1993. Glucuronidation of thyroid hormone by human bilirubin and phenol UDP-glucuronyltransferase isoenzymes. FEBS Lett. 324(3):358–360.
  • Visser TJ, Kaptein E, van Raaij JAGM, Joe CTT, Ebner T, Burchell B. 1993. Multiple UDP-glucuronyltransferases for the glucuronidation of thyroid hormone with preference for 3,3',5'-triiodothyronine (reverse T3). FEBS Lett. 315(1):65–68.
  • Visser TJ, Kaptein E, van Toor H, van Raaij JA, van den Berg KJ, Joe CT, van Engelen JG, Brouwer A. 1993. Glucuronidation of thyroid hormone in rat liver: effects of in vivo treatment with microsomal enzyme inducers and in vitro assay conditions. Endocrinology. 133(5):2177–2186.
  • Vranckx R, Rouaze M, Savu L, Nunez EA, Beaumont C, Flink IL. 1990. The hepatic biosynthesis of rat thyroxine binding globulin (TBG): demonstration, ontogenesis, and up-regulation in experimental hypothyroidism. Biochem Biophys Res Commun. 167(1):317–322.
  • Vulsma T, Gons MH, De Vijlder JJM. 1989. Maternal-fetal transfer of thyroxine in congenital hypothyroidism due to a total organification defect or thyroid agenesis. N Engl J Med. 321(1):13–16.
  • Wang J, Hallinger DR, Murr AS, Buckalew AR, Lougee RR, Richard AM, Laws SC, Stoker TE. 2019. High-throughput screening and chemotype-enrichment analysis of ToxCast phase II chemicals evaluated for human sodium-iodide symporter (NIS) inhibition. Environ Int. 126:377–386.
  • Wang J, Hallinger DR, Murr AS, Buckalew AR, Simmons SO, Laws SC, Stoker TE. 2018. High-throughput screening and quantitative chemical ranking for sodium-iodide symporter inhibitors in ToxCast phase i chemical library. Environ Sci Technol. 52(9):5417–5426.
  • World Health Organisation – International Programme on Chemical Safety. [WHO IPCS]. 2009. Principles and methods for the risk assessment of chemicals in food. World Health Organisation Environmental Health Criteria. Food and Agriculture Organisations of the United Nations. Vol. 240. p. 1–45.
  • Wu SY, Green WL, Huang WS, Hays MT, Chopra IJ. 2005. Alternate pathways of thyroid hormone metabolism. Thyroid. 15(8):943–958.
  • Zevenbergen C, Meima ME, Lima de Souza EC, Peeters RP, Kinne A, Krause G, Visser WE, Visser TJ. 2015. Transport of iodothyronines by human l-type amino acid transporters. Endocrinology. 156(11):4345–4355.
  • Zhou J, Zhang J, Xie W. 2005. Xenobiotic nuclear receptor-mediated regulation of UDP-glucuronosyl-transferases. Curr Drug Metab. 6(4):289–298.
  • Zuang V, Dura A, Bofill DA, Barroso J, Batista Leite S, Berggren E, Bernasconi C, Bopp S, Bowe G, Campia I, et al. 2019. EURL ECVAM status report on the development, validation and regulatory acceptance of alternative methods and approaches. EUR 30100 EN, Luxembourg: Publications Office of the EU. (JRC119292).